UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

798-P: Shift to a Lower BMI Category Is Associated with Improved Cardiometabolic Measures in Adults with T2D Treated with Tirzepatide

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Phenotype-Genotype Correlation in 56 Women with Nonclassical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency

The journal of clinical endocrinology and metabolism, 2001-01, Vol.86 (1), p.207-213

2001

Volltextzugriff (PDF)

726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12months

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2373-2382

2022

Volltextzugriff (PDF)

672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2373-2382

2022

Volltextzugriff (PDF)

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12), p.3453-3464

2023

Volltextzugriff (PDF)

The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12), p.3465-3477

2023

Volltextzugriff (PDF)

Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study

Diabetes therapy, 2022-02, Vol.13 (2), p.287-299

2022

Volltextzugriff (PDF)

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy

Journal of medical economics, 2024-12, Vol.27 (1), p.866-879

2024

Volltextzugriff (PDF)

Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure

European journal of endocrinology, 2009-07, Vol.161 (1), p.179

2009

Volltextzugriff (PDF)

McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases

European journal of endocrinology, 1994-09, Vol.131 (3), p.229

1994

Volltextzugriff (PDF)

Partnering For Pain: a Priority Setting Partnership to identify patient-oriented research priorities for pediatric chronic pain in Canada

CMAJ open, 2019-10, Vol.7 (4), p.E654-E664

2019

Volltextzugriff (PDF)

Plasma exchanges overcome persistent iodine overload to enable 131I ablation of differentiated thyroid carcinoma

Thyroid (New York, N.Y.), 2008-04, Vol.18 (4), p.469

2008

Volltextzugriff (PDF)

Partnering with Youth and Parents for the Greatest Impact of Top Patient-Oriented Priorities in Pediatric Chronic Pain Research, Care and Policy

Healthcare quarterly (Toronto, Ont.), 2022-04, Vol.24 (SP), p.18

2022

Volltextzugriff (PDF)

Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis

European journal of endocrinology, 1995-08, Vol.133 (2), p.166

1995

Volltextzugriff (PDF)

Redox Control of a Dendritic Ferrocenyl-Based Homogeneous Catalyst

Angewandte Chemie (International ed.), 2015-01, Vol.54 (1), p.311-314

International ed. in English, 2015

Volltextzugriff (PDF)

Characterization of small fiber pathology in a mouse model of Fabry disease

eLife, 2018-10, Vol.7

2018

Volltextzugriff (PDF)

Extrem rechte und rassistische Gewalt: Auswirkungen – Bewältigungsstrategien – Konsequenzen

2024

Volltextzugriff (PDF)

Comparison of the Serion IgM ELISA and Microscopic Agglutination Test for diagnosis of Leptospira spp. infections in sera from different geographical origins and estimation of Leptospira seroprevalence in the Wiwa indigenous population from Colombia

PLoS neglected tropical diseases, 2022-06, Vol.16 (6), p.e0009876-e0009876

2022

Volltextzugriff (PDF)

The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat

EMBO molecular medicine, 2018-03, Vol.10 (3), p.n/a

2018

Volltextzugriff (PDF)

Rituximab Impairs B Cell Response But Not T Cell Response to COVID‐19 Vaccine in Autoimmune Diseases

Arthritis & rheumatology (Hoboken, N.J.), 2022-06, Vol.74 (6), p.927-933

2022

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(157)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

798-P: Shift to a Lower BMI Category Is Associated with Improved Cardiometabolic Measures in Adults with T2D Treated with Tirzepatide

Phenotype-Genotype Correlation in 56 Women with Nonclassical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency

726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses

746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis

738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12months

672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months

The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study

The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy

Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure

McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases

Partnering For Pain: a Priority Setting Partnership to identify patient-oriented research priorities for pediatric chronic pain in Canada

Plasma exchanges overcome persistent iodine overload to enable 131I ablation of differentiated thyroid carcinoma

Partnering with Youth and Parents for the Greatest Impact of Top Patient-Oriented Priorities in Pediatric Chronic Pain Research, Care and Policy

Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis

Redox Control of a Dendritic Ferrocenyl-Based Homogeneous Catalyst

Characterization of small fiber pathology in a mouse model of Fabry disease

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Extrem rechte und rassistische Gewalt: Auswirkungen – Bewältigungsstrategien – Konsequenzen

Comparison of the Serion IgM ELISA and Microscopic Agglutination Test for diagnosis of Leptospira spp. infections in sera from different geographical origins and estimation of Leptospira seroprevalence in the Wiwa indigenous population from Colombia

The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat

Rituximab Impairs B Cell Response But Not T Cell Response to COVID‐19 Vaccine in Autoimmune Diseases

Suchergebnisse filtern